Abstract:Breast cancer affects around 13% of women. Breast cancer gene 1 (BRCA1) carriers are prone to lung and lymph node metastasis, while breast cancer gene 2 (BRCA2) carriers tend to have bone metastasis. Findings of pulmonary nodules, mediastinal lymphadenopathy, and elevated markers such as cancer antigen (CA) 15-3 and CA 27-29 suggest metastatic disease. Here, we present the case of a patient with BRCA1-positive breast cancer in remission and a history of ovarian cancer with mediastinal lymphadenopathy and pulmonary nodules, with avid fluorodeoxyglucose uptake on positron emission tomography (PET) scan and elevated CA 15-3 and CA 27-29. A 70-year-old female with a history of bilateral breast and ovarian cancer and a positive BRCA test presented with pulmonary nodules, mediastinal lymphadenopathy, and elevated CA 15-3 and CA 27-29. Imaging showed mediastinal and hilar lymphadenopathy. A PET scan revealed increased metabolic activity in the lymph nodes and pulmonary lesions. Fiberoptic bronchoscopy and endobronchial ultrasound lymph node sampling demonstrated granulomatous inflammation without malignant cells. The patient underwent a therapeutic trial of steroids with clinical improvement of symptoms and decreased hypermetabolic activity in chest lesions, as well as a decrease in tumor markers. The coexistence of sarcoidosis and breast cancer is rare; sarcoidosis can coexist, precede, or appear after breast cancer. In both conditions, tumor markers and PET avidity are seen, which makes diagnosis and management challenging. In case of ambiguity, biopsy is crucial. This case underscores the importance of integrating clinical, pathological, and imaging data to reach an accurate diagnosis and consider a therapeutic trial of steroids. Furthermore, the early PET response to treatment can be pivotal in differentiating between sarcoidosis and malignancy, especially in complex clinical scenarios. Proper differentiation is paramount to avoid therapeutic missteps and ensure appropriate patient management.

Recurrent Ovarian Carcinoma Presenting As a Solitary Sternal Metastasis on FDG PET/CT.

Occult Breast Cancer Presenting as Sternum Pain

Intraductal Carcinoma and Carcinosarcoma with Bone Metastases Presenting in One Breast: A Case Report.

An unusual presentation of solitary ovarian metastasis from colorectal cancer in an elderly woman: a case report

Calcified metastases from ovarian carcinoma highlighted by F-18 FDG PET/CT: report of two cases

Primary Liver Carcinosarcoma and 18F-FDG PET/CT.

Rare Case of Metachronous Gastric Metastasis from Primary Ovarian Carcinoma

A case of solitary metastatic colon adenocarcinoma of the sternum: an unusual metastatic site

Acute Small Bowel Obstruction: a Rare Initial Presentation for the Metastasis of the Large-Cell Carcinoma of the Lung.

Focal Uptake in the Sternum on 18F-FDG-PET/CT Caused by G-CSF Therapy after Chemotherapy Mimicking Bone Metastasis of Breast Cancer

Primary ovarian neuroendocrine carcinoma expressing substantially intense 18F-FDG uptake: A case report

Extraosseous Osteosarcoma of the Liver Demonstrated on 18F-FDG PET/CT Imaging.

Value of 18F-FDG PET/CT Imaging in Detection of Postoperative Recurrent or Metastasis of Ovarian Cancer

Value of ~(18)F-FDG PET/CT Imaging in Detection of Postoperative Recurrent or Metastasis of Ovarian Cancer

FDG PET/CT in Solitary Isolated Renal Metastasis From Squamous Cell Lung Cancer

Metaplastic Squamous Cell Carcinoma of Breast Demonstrated on 18F-FDG PET/CT.

Hypermetabolic Pulmonary and Mediastinal Lesions With Elevated Cancer Antigen (CA) 15-3 and CA 27-29 in a Patient With a History of Ovarian and Breast Cancer

A Case of Pancreatic Carcinosarcoma Detected on PET/CT.

Isolated Diffuse Bone Marrow Metastases From Signet-ring Cell Gastric Carcinoma

Case Report: a rare primary gastric choriocarcinoma revealed on 18F-FDG PET/CT

Ovarian serous carcinoma with stomach metastasis: a rare case report and literature review